MXPA04000249A - Metodos para tratamiento de trastornos cognitivos y menopausicos con d-treo-metilfenidato. - Google Patents
Metodos para tratamiento de trastornos cognitivos y menopausicos con d-treo-metilfenidato.Info
- Publication number
- MXPA04000249A MXPA04000249A MXPA04000249A MXPA04000249A MXPA04000249A MX PA04000249 A MXPA04000249 A MX PA04000249A MX PA04000249 A MXPA04000249 A MX PA04000249A MX PA04000249 A MXPA04000249 A MX PA04000249A MX PA04000249 A MXPA04000249 A MX PA04000249A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- cognitive
- threo methylphenidate
- treatment
- methylphenidate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En un aspecto, la presente invencion se refiere a metodos para tratamiento de la fatiga, lentitud neuroconductal y otros trastornos cognitivos y defectos debidos a canceres y tratamientos asociados con canceres y estados similares. En otro aspecto, la presente invencion se refiere a metodos para tratar trastornos relacionados con la menopausia, que incluyen defectos de funciones ejecutivas. Los metodos suponen la administracion de una composicion que comprende D-treo-metilfenidato que esta substancialmente libre de L-treo-metilfenidato y formas eritro de metilfenidato.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/903,803 US6486177B2 (en) | 1995-12-04 | 2001-07-12 | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
PCT/US2002/022039 WO2003005962A2 (en) | 2001-07-12 | 2002-07-11 | Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04000249A true MXPA04000249A (es) | 2004-05-04 |
Family
ID=25418099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04000249A MXPA04000249A (es) | 2001-07-12 | 2002-07-11 | Metodos para tratamiento de trastornos cognitivos y menopausicos con d-treo-metilfenidato. |
Country Status (10)
Country | Link |
---|---|
US (7) | US6486177B2 (es) |
EP (1) | EP1411943A4 (es) |
JP (1) | JP2005520780A (es) |
KR (1) | KR20040029360A (es) |
AU (1) | AU2002318302B2 (es) |
CA (1) | CA2453510C (es) |
IL (1) | IL159313A0 (es) |
MX (1) | MXPA04000249A (es) |
NZ (2) | NZ530211A (es) |
WO (1) | WO2003005962A2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0840610A1 (en) | 1995-07-14 | 1998-05-13 | Medeva Europe Limited | Composition comprising d-threo-methylphenidate and another drug |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
US20020035139A1 (en) * | 2000-06-20 | 2002-03-21 | Herbst Arthur L. | COX-2 inhibitors and the prevention of the side effects of radiation therapy |
FR2823975B1 (fr) * | 2001-04-27 | 2003-05-30 | Sanofi Synthelabo | Nouvelle utilisation de pyridoindolone |
CN1867359B (zh) * | 2003-10-08 | 2010-12-15 | 马林克罗特公司 | 哌甲酯溶液及其制药用途和制备方法 |
US20050239830A1 (en) * | 2004-04-26 | 2005-10-27 | Vikram Khetani | Methods of diminishing co-abuse potential |
WO2006012476A2 (en) * | 2004-07-22 | 2006-02-02 | Wyeth | Method for treating nervous system disorders and conditions |
WO2006012477A1 (en) * | 2004-07-22 | 2006-02-02 | Wyeth | Method for treating nervous system disorders and conditions |
CA2574310A1 (en) * | 2004-07-22 | 2006-02-02 | Wyeth | Method for treating nervous system disorders and conditions |
US20060100243A1 (en) * | 2004-10-22 | 2006-05-11 | Mark Froimowitz | Methylphenidate analogs and methods of use thereof |
EP1830648A4 (en) * | 2004-12-09 | 2008-03-12 | Celgene Corp | TREATMENT WITH D-THREO-METHYLPHENIDATE |
CN101123965B (zh) * | 2005-01-20 | 2012-08-22 | 分子药物研究所公司 | 哌甲酯衍生物及其应用 |
AU2006206410B2 (en) * | 2005-01-20 | 2012-08-30 | Ampio Pharmaceuticals, Inc. | Methylphenidate derivatives and uses of them |
EP1904059A2 (en) * | 2005-07-21 | 2008-04-02 | Wyeth a Corporation of the State of Delaware | Method for treating nervous system disorders and conditions |
RU2435569C2 (ru) | 2006-03-16 | 2011-12-10 | Трис Фарма, Инк. | Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола |
US8217047B2 (en) | 2008-05-27 | 2012-07-10 | Dmi Acquisition Corp. | Therapeutic methods and compounds |
US9345558B2 (en) | 2010-09-03 | 2016-05-24 | Ormco Corporation | Self-ligating orthodontic bracket and method of making same |
US20120238590A1 (en) * | 2010-09-13 | 2012-09-20 | Tenera Therapeutics, LLC Delaware | Compositions for treating cancer-related fatigue and methods of screening thereof |
US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
JP6290081B2 (ja) * | 2011-09-15 | 2018-03-07 | フリウルケム、ソシエタ、ペル、アチオニFriulchem Spa | 動物への経口投与用組成物、その製造方法およびその使用 |
KR101312286B1 (ko) * | 2012-11-26 | 2013-09-27 | (주)비씨월드제약 | 즉시방출 및 조절방출 특성을 갖고 d-트레오-메틸페니데이트를 포함하는 약학 조성물 |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US105134A (en) * | 1870-07-05 | Thomas sheehan | ||
US19535A (en) * | 1858-03-02 | Improvement in sewing-machines | ||
US32335A (en) * | 1861-05-14 | Island | ||
US49205A (en) * | 1865-08-01 | Improvement in machines for hulling grain | ||
US2507631A (en) | 1944-01-19 | 1950-05-16 | Ciba Pharm Prod Inc | Pyridine and piperidine compounds and process of making same |
GB589625A (en) | 1944-01-19 | 1947-06-25 | Chem Ind Basel | Manufacture of new pyridine and piperidine compounds |
US2838519A (en) * | 1953-12-23 | 1958-06-10 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
GB788226A (en) | 1953-12-23 | 1957-12-23 | Ciba Ltd | Stereoisomers of ª‡-phenyl-ª‡-piperidyl-(2)-acetic acid and process of making same |
US2957880A (en) | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
GB878167A (en) | 1958-11-17 | 1961-09-27 | Ciba Ltd | New acetic acid esters |
SU466229A1 (ru) | 1973-01-23 | 1975-04-05 | Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе | Способ получени гидрохлорида метилового эфира трео- -фенил- (пиперидил-2)-уксусной кислоты |
US4137300A (en) * | 1976-08-20 | 1979-01-30 | Ciba-Geigy Corporation | Sustained action dosage forms |
US4410700A (en) * | 1980-07-03 | 1983-10-18 | The United States Of America As Represented By The Department Of Health And Human Services | Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution |
DE3279999D1 (en) * | 1981-09-30 | 1989-11-30 | Nat Res Dev | Compositions comprising encapsulated particles |
US4904476A (en) * | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4794001A (en) * | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4986987A (en) * | 1986-05-09 | 1991-01-22 | Alza Corporation | Pulsed drug delivery |
US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5236689A (en) * | 1987-06-25 | 1993-08-17 | Alza Corporation | Multi-unit delivery system |
US5391381A (en) * | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
US5283193A (en) | 1988-06-27 | 1994-02-01 | Asahi Kasei Kogyo K.K. | Process for producing optically active α-substituted organic acid and microorganism and enzyme used therefor |
SE509029C2 (sv) * | 1988-08-16 | 1998-11-30 | Ss Pharmaceutical Co | Långtidsverkande diklofenak-natriumpreparat |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5217718A (en) | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
US5284769A (en) | 1989-10-16 | 1994-02-08 | Chiros Ltd. | Process for preparing a single enantiomer of a lactam using lactamase |
US5362755A (en) | 1990-01-05 | 1994-11-08 | Sepracor, Inc. | Method for treating asthma using optically pure (R)-albuterol |
US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
JP2558396B2 (ja) * | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
US5104899A (en) | 1990-08-13 | 1992-04-14 | Sepracor, Inc. | Methods and compositions for treating depression using optically pure fluoxetine |
US5232705A (en) * | 1990-08-31 | 1993-08-03 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
US5160744A (en) * | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
WO1993006821A1 (en) * | 1991-10-04 | 1993-04-15 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained-release tablet |
EP0546593B1 (en) * | 1991-10-30 | 1997-09-03 | Glaxo Group Limited | Multi-layered compositions containing histamine or serotonin antagonists |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5223265A (en) * | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5308348A (en) * | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5331000A (en) | 1992-03-09 | 1994-07-19 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen |
US5299121A (en) * | 1992-06-04 | 1994-03-29 | Medscreen, Inc. | Non-prescription drug medication screening system |
US5512293A (en) * | 1992-07-23 | 1996-04-30 | Alza Corporation | Oral sustained release drug delivery device |
ES2284740T3 (es) | 1992-08-03 | 2007-11-16 | Sepracor Inc. | Carboxilato de terfenadina y el tratamiento de la irritacion cutanea. |
US5376384A (en) * | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
JP3091618B2 (ja) | 1993-01-29 | 2000-09-25 | 四郎 小林 | 開環重合法および開環重合用酵素触媒 |
JP2916978B2 (ja) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
IT1276689B1 (it) | 1995-06-09 | 1997-11-03 | Applied Pharma Res | Forma farmaceutica solida ad uso orale |
CA2223629A1 (en) | 1995-07-14 | 1997-02-06 | Nicholas Robert Pope | Therapeutic use of d-threo-methylphenidate |
EP0840610A1 (en) * | 1995-07-14 | 1998-05-13 | Medeva Europe Limited | Composition comprising d-threo-methylphenidate and another drug |
GB9514451D0 (en) | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
US6355656B1 (en) * | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5733756A (en) | 1996-01-05 | 1998-03-31 | Celgene Corporation | Lactams and processes for stereoselective enrichment of lactams, amides, and esters |
MX9805870A (es) | 1996-01-22 | 1999-01-31 | ||
US6242464B1 (en) | 1996-01-22 | 2001-06-05 | Chiroscience Limited | Single isomer methylphenidate and resolution process |
EP0879228B1 (en) | 1996-02-02 | 2002-10-30 | Medeva Europe Limited | Process for the preparation of d-threo-(r,r)-methyl phenidate and recycling of undesired enantiomers by epimerisation |
GB9604943D0 (en) * | 1996-03-08 | 1996-05-08 | Chiroscience Ltd | Resolution |
ATE212336T1 (de) | 1996-03-08 | 2002-02-15 | Medeva Europ Ltd | Auflösungsverfahren von threo-methylphenidate |
GB9606417D0 (en) * | 1996-03-27 | 1996-06-05 | Chiroscience Ltd | Asymmetric cyclisation |
AU5267698A (en) | 1996-11-25 | 1998-06-22 | Alza Corporation | Ascending-dose dosage form |
CZ206299A3 (cs) | 1996-12-13 | 1999-09-15 | Medeva Europe Limited | Způsob přípravy enantiomerně obohaceného THREO-metalfenidátu |
GB9700912D0 (en) | 1997-01-17 | 1997-03-05 | Chiroscience Ltd | Resolution |
US5965734A (en) * | 1997-01-31 | 1999-10-12 | Celgene Corporation | Processes and intermediates for preparing 2-substituted piperidine stereoisomers |
US5936091A (en) * | 1997-05-22 | 1999-08-10 | Celgene Corporation | Processes and intermediates for resolving piperidyl acetamide stereoisomers |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
ID29852A (id) * | 1998-11-02 | 2001-10-18 | Elan Corp Plc Cs | Komposisi pelepasan modifikasi multi partikulasi |
US6395752B1 (en) * | 1999-03-04 | 2002-05-28 | Pharmaquest Limited | Method of treating depression using 1-threo-methylphenidate |
US6127385A (en) * | 1999-03-04 | 2000-10-03 | Pharmaquest Limited | Method of treating depression using l-threo-methylphenidate |
GB9913458D0 (en) | 1999-06-09 | 1999-08-11 | Medeva Europ Ltd | The therapeutic use of d-threo-methylphenidate |
ATE252903T1 (de) | 1999-12-17 | 2003-11-15 | Celltech Pharma Europ Ltd | Arzneimittel zur behandlung konvulsivischer zustände |
US6221883B1 (en) * | 2000-04-12 | 2001-04-24 | Ross Baldessarini | Method of dopamine inhibition using l-threo-methylphenidate |
US20020132793A1 (en) * | 2000-08-28 | 2002-09-19 | Mel Epstein | Use of methylphenidate compounds to enhance memory |
US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
US6359139B1 (en) * | 2000-11-07 | 2002-03-19 | Celgene Corporation | Methods for production of piperidyl acetamide stereoisomers |
-
2001
- 2001-07-12 US US09/903,803 patent/US6486177B2/en not_active Expired - Fee Related
-
2002
- 2002-07-11 NZ NZ530211A patent/NZ530211A/en not_active IP Right Cessation
- 2002-07-11 IL IL15931302A patent/IL159313A0/xx unknown
- 2002-07-11 JP JP2003511771A patent/JP2005520780A/ja active Pending
- 2002-07-11 KR KR10-2004-7000312A patent/KR20040029360A/ko not_active Application Discontinuation
- 2002-07-11 NZ NZ565754A patent/NZ565754A/en not_active IP Right Cessation
- 2002-07-11 EP EP02748129A patent/EP1411943A4/en not_active Withdrawn
- 2002-07-11 AU AU2002318302A patent/AU2002318302B2/en not_active Ceased
- 2002-07-11 MX MXPA04000249A patent/MXPA04000249A/es active IP Right Grant
- 2002-07-11 WO PCT/US2002/022039 patent/WO2003005962A2/en active IP Right Grant
- 2002-07-11 CA CA2453510A patent/CA2453510C/en not_active Expired - Fee Related
- 2002-07-16 US US10/195,974 patent/US7115631B2/en not_active Expired - Fee Related
-
2004
- 2004-04-08 US US10/820,397 patent/US20040204456A1/en not_active Abandoned
-
2006
- 2006-04-11 US US11/402,385 patent/US20060183774A1/en not_active Abandoned
-
2009
- 2009-12-17 US US12/640,734 patent/US20100093797A1/en not_active Abandoned
-
2011
- 2011-06-30 US US13/172,977 patent/US20110257227A1/en not_active Abandoned
-
2012
- 2012-10-26 US US13/661,472 patent/US20130053414A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003005962A3 (en) | 2003-06-12 |
NZ530211A (en) | 2008-04-30 |
US20020022640A1 (en) | 2002-02-21 |
US20130053414A1 (en) | 2013-02-28 |
CA2453510A1 (en) | 2003-01-23 |
KR20040029360A (ko) | 2004-04-06 |
NZ565754A (en) | 2009-05-31 |
EP1411943A2 (en) | 2004-04-28 |
CA2453510C (en) | 2012-03-20 |
US7115631B2 (en) | 2006-10-03 |
IL159313A0 (en) | 2004-06-01 |
JP2005520780A (ja) | 2005-07-14 |
EP1411943A4 (en) | 2005-09-28 |
US6486177B2 (en) | 2002-11-26 |
AU2002318302B2 (en) | 2007-03-15 |
WO2003005962A2 (en) | 2003-01-23 |
US20110257227A1 (en) | 2011-10-20 |
US20020198234A1 (en) | 2002-12-26 |
AU2002318302C1 (en) | 2003-01-29 |
US20040204456A1 (en) | 2004-10-14 |
US20100093797A1 (en) | 2010-04-15 |
US20060183774A1 (en) | 2006-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04000249A (es) | Metodos para tratamiento de trastornos cognitivos y menopausicos con d-treo-metilfenidato. | |
AR055810A1 (es) | Uso de inhibidores de acetilcolinesterasa e inhibidores de la produccion de beta-app o acumulacion de a-beta | |
IL280818B (en) | A methods of producing alpha-galactosidase preparations | |
ATE475418T1 (de) | O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen | |
MX9704793A (es) | Metodos y composiciones para tratar rinitis alergica y otros trastornos usando descarboetoxiloratadina. | |
ATE328588T1 (de) | Behandlung von nicotinsucht und sucht bedingtem verhalten | |
MY180733A (en) | Method of using ?-hydroxy-?-methybutyrate | |
MX9706969A (es) | 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos. | |
UA85055C2 (ru) | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний | |
WO2004071431A3 (en) | Method and composition for treating neurodegenerative disorders | |
WO2006001877A3 (en) | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen | |
BR9814923A (pt) | Método para tratamento de doença de alzheimer | |
UA70925C2 (uk) | Спосіб лікування естрогенстимульованого раку | |
HK1071890A1 (en) | Spiroazacyclic compounds as monoamine receptor modulators | |
WO2006042249A3 (en) | Methods and compositions for treating migraine pain | |
IL144643A0 (en) | Jak-3 inhibitors for treating allergic disorders | |
PL330496A1 (en) | Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy | |
WO2003015713A3 (en) | Treatment of glial tumors with glutamate antagonists | |
MXPA05007379A (es) | Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos. | |
TN2011000228A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
EP2286817A3 (en) | Method of treating functional bowel disorders | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
TW200616639A (en) | Methods for treating a mammal before, during and after cardiac arrest | |
MXPA02004701A (es) | Sales de hidroxieicosatetraenoato, composiciones y metodos de uso para tratar trastornos de resequedad en los ojos. | |
IL144315A0 (en) | Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |